CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals, Inc. is a pre-clinical stage biotech company focused on developing novel treatments for brain tumors. The company is currently in the process of developing treatments for both primary and metastatic cancers of the brain and central nervous system. Their lead drug candidate, Berubicin, is particularly targeted at the treatment of glioblastoma multiforme (GBM), an aggressive and currently incurable form of brain cancer. CNS Pharmaceuticals holds a worldwide exclusive license to the Berubicin chemical compound, obtained from Reata Pharmaceuticals, Inc., and has acquired all data and know-how related to a completed Phase 1 trial with Berubicin in GBM conducted in 2006. The trial demonstrated a 44% disease control rate based on 11 patients with stable disease, plus responders, and one patient even achieved a durable complete response, remaining cancer-free as of February 2020. In the second half of 2020, CNS Pharmaceuticals plans to commence a Phase 2 clinical trial of Berubicin for GBM treatment in the U.S., while a sub-licensee partner will undertake a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. The company's second drug candidate, WP1244, has shown promising results in preclinical studies, being 500-times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. Founded in 2017, CNS Pharmaceuticals operates in the Biotechnology and Pharmaceutical industries with its headquarters in the United States. The latest investment in the company was a Post-IPO Equity investment at 14 June 2024. For more information, please visit www.cnspharma.com.